MTOR

Meritor Launches ProTec™ Independent Front Suspension for Motorcoach Applications

Retrieved on: 
Thursday, June 9, 2022

TROY, Mich., June 9, 2022 /PRNewswire/ -- Meritor, Inc. (NYSE: MTOR) today announced the launch of its ProTec™ Independent Front Suspension (IFS) for motorcoach applications. The new IFS MIS-20E is Meritor's first suspension specifically designed for the ride quality and heavy load requirements of motorcoaches. Based on field-proven technology, this product is Meritor's first fully integrated suspension and steering system made to be a drop-in replacement for bus and coach manufacturers.

Key Points: 
  • TROY, Mich., June 9, 2022 /PRNewswire/ -- Meritor, Inc. (NYSE:MTOR) today announced the launch of its ProTec Independent Front Suspension (IFS) for motorcoach applications.
  • The new IFS MIS-20E is Meritor's first suspension specifically designed for the ride quality and heavy load requirements of motorcoaches.
  • Based on field-proven technology, this product is Meritor's first fully integrated suspension and steering system made to be a drop-in replacement for bus and coach manufacturers.
  • Meritor, Inc. is a leading global supplier of drivetrain, mobility, braking , aftermarket and electric powertrain solutions for commercial vehicle and industrial markets.

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference

Retrieved on: 
Wednesday, June 1, 2022

LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022.

Key Points: 
  • LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022.
  • Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fireside chat at 10am ET on Thursday, June 9, 2022.
  • Aadi is a biopharmaceutical company focused on precision therapies for genetically defined cancers.
  • More information on Aadis development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn .

Meritor Wins Three Gold Telly Awards for 14Xe™ Electric Powertrain Commercial

Retrieved on: 
Wednesday, June 1, 2022

TROY, Mich., June 1, 2022 /PRNewswire/ -- Meritor, Inc. (NYSE: MTOR) announced that The Road Ahead, a video production created to showcase the company's 14Xe™ electric powertrain, was recognized with three gold awards in the 43rd Annual Telly Awards.

Key Points: 
  • TROY, Mich., June 1, 2022 /PRNewswire/ -- Meritor, Inc. (NYSE: MTOR) announced that The Road Ahead, a video production created to showcase the company's 14Xe electric powertrain, was recognized with three gold awards in the 43rd Annual Telly Awards.
  • "Now, more than ever, it is necessary to celebrate video work that reflects the top tier of ourindustry, such as Meritor," says Telly Awards Executive Director Sabrina Dridje.
  • "We released The Road Ahead to coincide with the production launch of our 14Xe electric powertrain," said Krista Sohm, chief marketing and communication officer at Meritor.
  • Meritor, Inc. is a leading global supplier of drivetrain, mobility, braking , aftermarket and electric powertrain solutions for commercial vehicle and industrial markets.

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Retrieved on: 
Tuesday, May 31, 2022

LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications.

Key Points: 
  • LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications.
  • We are delighted to welcome Marcy to the team, as she brings extensive experience to the senior role of investor relations and corporate communications and a strong history of relationship building with investors and other key external audiences, said Neil Desai, PhD, Founder, President and Chief Executive Officer of Aadi Bioscience.
  • Ms. Graham brings more than 20 years of biotech and pharma-specific investor relations and corporate communications experience, leading these functional areas at companies in all stages of development.
  • She joins Aadi after most recently serving as the Vice President of Corporate Affairs at Poseida Therapeutics and previously as Vice President IR and Corporate Communications at Mirati Therapeutics.

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Wednesday, May 18, 2022

The recorded presentation will also be available for 90 days on Aadis website within the News/Events & Presentations section.

Key Points: 
  • The recorded presentation will also be available for 90 days on Aadis website within the News/Events & Presentations section.
  • Aadi is a biopharmaceutical company focused on precision therapies for genetically-defined cancers.
  • In November 2021, Aadi received FDA approval for FYARRO for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), and in February 2022Aadi announced the commercial launch of FYARRO in this indication.
  • More information on Aadis development pipeline is available on the Aadi website at www.aadibio.com .

Meritor Launches Power Control and Accessory System (PCAS) for Zero Emissions Commercial Vehicles

Retrieved on: 
Monday, May 9, 2022

TROY, Mich., May 9, 2022 /PRNewswire/ -- Meritor, Inc. (NYSE: MTOR) today announced the production launch of its Power Control and Accessory System (PCAS) for zero emissions commercial vehicles.

Key Points: 
  • TROY, Mich., May 9, 2022 /PRNewswire/ -- Meritor, Inc. (NYSE: MTOR) today announced the production launch of its Power Control and Accessory System (PCAS) for zero emissions commercial vehicles.
  • The system provides intelligent electrification providing power where needed and control over sub-systems and accessories.
  • Designed for flexibility to meet the application requirements of commercial vehicles, the PCAS enables:
    Meritor will showcase the PCAS in booth No.
  • Meritor, Inc. is a leading global supplier of drivetrain, mobility, braking , aftermarket and electric powertrain solutions for commercial vehicle and industrial markets.

Meritor Announces Production Milestones for its 14Xe™ Electric Powertrain

Retrieved on: 
Monday, May 9, 2022

TROY, Mich., May 9, 2022 /PRNewswire/ -- Meritor, Inc. (NYSE: MTOR) today announced production milestones for its 14XeePowertrain.

Key Points: 
  • TROY, Mich., May 9, 2022 /PRNewswire/ -- Meritor, Inc. (NYSE: MTOR) today announced production milestones for its 14XeePowertrain.
  • Nearly 300 electric powertrains have now been produced and assembled in Meritor's Asheville and Forest City, North Carolina facilities and approximately 350,000 miles have been logged on commercial vehicles equipped with the company's 14Xe single or tandem electric powertrain.
  • Meritor will showcase the 14Xe electric powertrain in booth No.
  • Meritor, Inc. is a leading global supplier of drivetrain, mobility, braking , aftermarket and electric powertrain solutions for commercial vehicle and industrial markets.

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

Retrieved on: 
Monday, May 9, 2022

Neil Desai, PhD, Founder, President and Chief Executive Officer of Aadi, stated, We are very pleased to have these leading NGS partnerships in place.

Key Points: 
  • Neil Desai, PhD, Founder, President and Chief Executive Officer of Aadi, stated, We are very pleased to have these leading NGS partnerships in place.
  • Recently published data project an incidence of approximately 12,000 advanced cancer patients with TSC1 or TSC2 definite impact alterations in the US.
  • These collaborations should help physicians to identify patients who may be candidates for nab-sirolimus in our PRECISION 1 registrational trial.
  • Aadi cautions you that certain statements included in this press release that are not a description of historical facts are forward-looking statements.

Franklin Electric Announces Chris Villavarayan Elected to be a Director of the Company

Retrieved on: 
Friday, May 6, 2022

FORT WAYNE, Ind., May 06, 2022 (GLOBE NEWSWIRE) -- The board of directors of Franklin Electric Co., Inc. (NASDAQ: FELE) has elected Chris Villavarayan to be a director of the Company effective May 6, 2022.

Key Points: 
  • FORT WAYNE, Ind., May 06, 2022 (GLOBE NEWSWIRE) -- The board of directors of Franklin Electric Co., Inc. (NASDAQ: FELE) has elected Chris Villavarayan to be a director of the Company effective May 6, 2022.
  • Mr. Villavarayan has been the Chief Executive Officer and President of Meritor, Inc. (NYSE: MTOR) since March 2021.
  • Franklin Electric is a global leader in the production and marketing of systems and components for the movement of water and fuel.
  • Recognized as a technical leader in its products and services, Franklin Electric serves customers around the world in residential, commercial, agricultural, industrial, municipal, and fueling applications.

MERITOR INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Meritor, Inc. - MTOR

Retrieved on: 
Wednesday, May 4, 2022

Kuznicki Law PLLC is investigating the proposed sale of Meritor, Inc. (NYSE: MTOR) to Cummins Inc. (NYSE: CMI).

Key Points: 
  • Kuznicki Law PLLC is investigating the proposed sale of Meritor, Inc. (NYSE: MTOR) to Cummins Inc. (NYSE: CMI).
  • Under the terms of the proposed transaction, shareholders of Meritor will receive only $36.50 in cash for each share of Meritor that they own.
  • If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email ( [email protected] ), or visit https://kclasslaw.com/cases/ma/nyse-mtor/ to learn more.
  • Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.